MilliporeSigma’s CHOZN® Expression System Selected for Bi-specific Antibody Development by SystImmune
- Accelerates development timelines with faster, easier selection andscale up of clones
- Delivers higher titers of recombinant proteins
Billerica, Massachusetts, May 16, 2017 — MilliporeSigma today announced that its CHOZN® expression system will be used by SystImmune, a Seattle-based biotechnology company, for commercial development of a bi-specific antibody therapeutic.
The CHOZN® expression system is designed to deliver manufacturing-ready robust and stable producing clones with a workflow that minimizes the resources needed to complete a cell line development project. As a result, users are able to quickly evaluate more molecules in their pipeline.
“When compared with alternate expression systems, our CHOZN® system offers a turnkey solution that consistently delivers shortened development timelines,” said Udit Batra, CEO, MilliporeSigma.
MilliporeSigma’s CHOZN® expression system is based on a GS -/- Chinese hamster ovary (CHO) cell line.
“With only two scientists in our cell science department, we were able to generate more than 10 stable cell lines using this platform in a single year,” said Camilla Wang, Scientist, SystImmune. “The CHOZN® platform outperformed other systems in many ways. It is easy to use, requires less time to generate final single cell clones, and most of all, the expression level is consistently higher compared to the other approaches.”
Along with the CHOZN® cells, MilliporeSigma provides an expression vector, extensive user protocols, a comprehensive cell line history document and paired cGMP media and feeds. Services are offered for cell line development in the CHOZN® expression system. MilliporeSigma also offers gene engineering services using its CompoZr™ zinc finger nuclease technology to engineer CHO cell lines with characteristics attractive to biopharmaceutical developers and manufacturers, including resistance to Centinel™ technology.
All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About the Life Science Business of Merck KGaA, Darmstadt, Germany
The life science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has 19,000 employees and 65 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery. Udit Batra is the global chief executive officer of MilliporeSigma.
Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.
Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck KGaA, Darmstadt, Germany, generated sales of € 15.0 billion in 66 countries.
Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the „Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
Merck KGaA, Darmstadt, Germany, officially opened its new Research Center for electronic applications on the campus of its headquarters in Darmstadt, Germany, today. With an investment of € 50 million ...